The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis


Autoři: Giusi Prencipe aff001;  Claudia Bracaglia aff001;  Ivan Caiello aff001;  Antonia Pascarella aff001;  Paola Francalanci aff002;  Manuela Pardeo aff001;  Alessandra Meneghel aff003;  Giorgia Martini aff003;  Marianna N. Rossi aff001;  Antonella Insalaco aff001;  Giulia Marucci aff001;  Valerio Nobili aff004;  Marco Spada aff005;  Francesco Zulian aff003;  Fabrizio De Benedetti aff001
Působiště autorů: Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy aff001;  Department of Pathology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy aff002;  Department of Woman and Child Health, University of Padua, Padua, Italy aff003;  Hepatology Gastroenterology and Nutrition Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy aff004;  Division of Abdominal Transplantation and Hepatobiliopancreatic Surgery, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy aff005
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226043

Souhrn

Aim of this study was to investigate the activation of the IFNγ pathway in the affected liver and in the blood of patients with secondary hemophagocytic lymphohistiocytosis (sHLH). To this purpose, the mRNA expression levels of IFNG and IFNγ-inducible genes as well as Tyrosine (701)-phosphorylated signal transducer and activator of transcription 1 (STAT1) protein levels were evaluated in the liver and in peripheral blood mononuclear cells (PBMCs) of three patients with sHLH with predominant liver involvement. The mRNA expression levels of IFNG and IFNγ-inducible genes were markedly higher in patient livers compared to control livers and to one disease control liver. Conversely, slight differences in the expression levels of Type I IFN-inducible genes and other classical inflammatory cytokine genes were found. Further supporting the activation of the IFNγ pathway, higher protein levels of phosphorylated and total STAT1 were detected in patient livers compared to control livers. When the expression of the same genes analysed in liver tissues was evaluated in PBMCs collected from 2 out of 3 patients before the liver biopsy, we found that mRNA levels of IFNγ-inducible genes were markedly increased. Accordingly, high circulating levels of IFNγ-inducible CXCL9 were observed in patients. Altogether, these data demonstrate the selective and marked up-regulation of the IFNγ pathway in the liver tissue and blood of patients with active sHLH. Finally, we show that measurement of circulating CXCL9 levels and evaluation of IFNγ–inducible gene expression levels in PBMCs may represent a new valid tool to better identify patients with suspected HLH with predominant liver involvement.

Klíčová slova:

Biopsy – Blood – Cytokines – Gene expression – Inflammatory diseases – Interferons – Liver diseases – T cells


Zdroje

1. Janka GE, Lehmberg K. Hemophagocytic syndromes—an update. Blood Rev. 2014;28(4):135–42. doi: 10.1016/j.blre.2014.03.002 24792320.

2. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15(1):172. doi: 10.1186/s12916-017-0930-5 28918754; PubMed Central PMCID: PMC5603161.

3. Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatric rheumatology online journal. 2017;15(1):5. doi: 10.1186/s12969-016-0130-4 28095869; PubMed Central PMCID: PMC5240371.

4. Yang SL, Xu XJ, Tang YM, Song H, Xu WQ, Zhao FY, et al. Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine. 2016;85:14–7. doi: 10.1016/j.cyto.2016.05.022 27269180.

5. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–43. doi: 10.1182/blood-2003-10-3413 15069016.

6. Pachlopnik Schmid J, Ho CH, Chretien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO molecular medicine. 2009;1(2):112–24. doi: 10.1002/emmm.200900009 20049711.

7. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the rheumatic diseases. 2017;76(1):166–72. doi: 10.1136/annrheumdis-2015-209020 27296321.

8. Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. The Journal of allergy and clinical immunology. 2018;141(4):1439–49. doi: 10.1016/j.jaci.2017.07.021 28807602.

9. Abdullatif H, Mohsen N, El-Sayed R, El-Mougy F, El-Karaksy H. Haemophagocytic lymphohistiocytosis presenting as neonatal liver failure: A case series. Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology. 2016;17(2):105–9. Epub 2016/07/12. doi: 10.1016/j.ajg.2016.06.002 27397412.

10. de Kerguenec C, Hillaire S, Molinie V, Gardin C, Degott C, Erlinger S, et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. The American journal of gastroenterology. 2001;96(3):852–7. Epub 2001/03/31. doi: 10.1111/j.1572-0241.2001.03632.x 11280564.

11. Guthery SL, Heubi JE. Liver involvement in childhood histiocytic syndromes. Current opinion in gastroenterology. 2001;17(5):474–8. Epub 2006/10/13. doi: 10.1097/00001574-200109000-00013 17031204.

12. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31. doi: 10.1002/pbc.21039 16937360.

13. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75(3):481–9. doi: 10.1136/annrheumdis-2015-208982 26865703.

14. Rice GI, Forte GM, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12(12):1159–69. doi: 10.1016/S1474-4422(13)70258-8 24183309; PubMed Central PMCID: PMC4349523.

15. Rice GI, Melki I, Fremond ML, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol. 2017;37(2):123–32. doi: 10.1007/s10875-016-0359-1 27943079; PubMed Central PMCID: PMC5325846.

16. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol. 2002;3(9):859–66. doi: 10.1038/ni828 12172544.

17. Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. Journal of immunology. 2003;170(9):4833–9. doi: 10.4049/jimmunol.170.9.4833 12707366.

18. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105(4):1648–51. doi: 10.1182/blood-2004-08-2997 15466922.

19. Chapin CA, Burn T, Meijome T, Loomes KM, Melin-Aldana H, Kreiger PA, et al. Indeterminate pediatric acute liver failure is uniquely characterized by a CD103+CD8+ T-cell infiltrate. Hepatology. 2018. Epub 2018/04/01. doi: 10.1002/hep.29901 29603342.

20. Schneier A, Stueck AE, Petersen B, Thung SN, Perumalswami P. An Unusual Cause of Acute Liver Failure: Three Cases of Hemophagocytic Lymphohistiocytosis Presenting at a Transplant Center. Semin Liver Dis. 2016;36(1):99–105. doi: 10.1055/s-0036-1571299 26870936.

21. Alonso EM, Horslen SP, Behrens EM, Doo E. Pediatric acute liver failure of undetermined cause: A research workshop. Hepatology. 2017;65(3):1026–37. doi: 10.1002/hep.28944 27862115; PubMed Central PMCID: PMC5372202.

22. Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, et al. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis. PLoS One. 2016;11(2):e0150075. doi: 10.1371/journal.pone.0150075 26914138; PubMed Central PMCID: PMC4767214.

23. Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y. Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis. Ital J Pediatr. 2016;42(1):50. doi: 10.1186/s13052-016-0262-7 27209435; PubMed Central PMCID: PMC4875745.

24. Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, et al. Use of a mouse model to identify a blood biomarker for IFNgamma activity in pediatric secondary hemophagocytic lymphohistiocytosis. Translational research: the journal of laboratory and clinical medicine. 2017;180:37–52 e2. doi: 10.1016/j.trsl.2016.07.023 27559680.

25. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. The Journal of allergy and clinical immunology. 2017;139(5):1698–701. Epub 2016/11/24. doi: 10.1016/j.jaci.2016.10.022 27876626; PubMed Central PMCID: PMC5846100.

26. Locatelli F, Jordan MB, Allen C, Cesareo S, Rizzari C, Anupama R et al. Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis. Blood. 2018;132(Suppl 1):LBA-6.

27. De Benedetti F, Brogan P, Grom A, Quartier P, Schneider R, De Graaf K et al. Emapalumab, an interferon gamma (IFN-y)-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann Rheum Dis. 2019 June;78 (S2). doi: 10.1136/annrheumdis-2019-eular.3341


Článek vyšel v časopise

PLOS One


2019 Číslo 12